Professional Documents
Culture Documents
Ifob Neo B
Ifob Neo B
Ifob Neo B
03)
Revision date : March 23, 2018
Concentration (ng/mL)
REFERENCES
Cross-reactivity materials 25 100 500
Cross-reactivity (%) 1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2020: Cancer
Bovine hemoglobin (2,000 ㎍/mL) 1.22 -0.84 1.12 incidence, motality and Prevalence worldwide. IARC CancerBase
Chicken hemoglobin (500 ㎍/mL) -2.55 0.09 1.11
no. 5, version 2.0. Lyon, France: IARC Pr; 2004.
2. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis
Fish hemoglobin (100 ㎍/mL) 0.83 3.35 -1.43
of colorectal cancer: implications for molecular diagnosis.
Horse(Equine) hemoglobin (500 ㎍/mL) -1.25 -1.17 0.81
Cancer 2005;104: 2035-2047.
Goat hemoglobin (500 ㎍/mL) 0.15 1.46 1.50 3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM,
Pig(Swine) hemoglobin (500 ㎍/mL) 0.62 -0.24 -0.87 Schuman LM, et al. Reducing mortality from colorectal cancer
Rabbit hemoglobin (500 ㎍/mL) -0.53 -0.48 -2.02 by scrrning for fecal occult blood. Minnesota Colon Cancer
Sheep hemoglobin (500 ㎍/mL) 1.91 0.17 -0.58 Control study. N Engl J Med 1993;328:1365-1371
- Interference 4. Kronborg O, Fenger C, Olden J, Jorgensen OD, Sondergaard O.
There was no significant interference from these materials with Randomised study of screening for colorectal cancer with fecal
the ichroma™ iFOB Neo test measurements. occult blood test. Lancet 1996;384: 1467-1471.
Concentration (ng/mL)
5. Hardcastle JD, Chamberlain J, Robinson MH, Moss SM, Amar SS,
Balfour TW, et al. Randomised controlled trial of fecal occult
Interference materials 25 100 500
blood screening for colorectal cancer. Lancet 1996;348: 1472-
Interference (%)
1477.
Ascorbic acid (350 µmol/L) 0.37 -1.66 0.92 6. Rozen P, Waked A, Vilkin A, et al. Evaluation of a desk top
Bilirubin (350 µmol/L) -4.03 0.01 1.41 instrument for the automated development and
Albumin (60 g/L) -1.99 -3.27 1.47 immunochemical quantification of fecal occult blood. Med Sci
Glucose (120 mg/dL) 1.47 -1.07 0.78 Moint 2006;12(6):MT27-32.
Triglyceride mixture (500 mg/dL) 0.72 -2.65 -2.40 Note: Please refer to the table below to identify various symbols
Precision
- Between Lot
One person tested three different lots of ichroma™ iFOB Neo,
five times at each concentration of the control standard.
- Between person
Three different persons tested one lot of ichroma™ iFOB Neo,
five times at each concentration of the control standard.
- Between site
One person tested one lot of ichroma™ iFOB Neo at three
different sites, five times at each concentration of the control
standard.
Hb Between-lot Between-person Between-day Between-site
(ng/mL) AVG CV(%) AVG CV(%) AVG CV(%) AVG CV(%)
25 24.90 6.03 24.68 6.06 25.12 6.84 24.11 7.88
100 99.84 3.32 100.78 4.20 98.52 3.60 100.15 3.50
500 501.36 1.99 506.49 1.76 499.48 2.45 496.16 2.22
Accuracy
The accuracy was confirmed by 3 different lots testing ten times
each different concentration.
Hb(ng/mL) Lot 1 Lot 2 Lot 3 AVG Recovery (%) For technical assistance; please contact:
25 24.89 24.26 24.73 24.62 98% Boditech Med Inc.’s Technical Services
100 100.18 101.32 99.84 100.44 100% Tel: +82 33 243-1400
500 503.76 496.10 507.90 502.59 101% E-mail: sales@boditech.co.kr
1,000
y = 1.0296x - 5.9682 Tel: +(32) -2-732-59-54
800
R = 0.9919 Fax: +(32) -2-732-60-03
600 E-Mail: mail@obelis.net
400
200
0
0 200 400 600 800 1,000
ichroma™ iFOB [ng/mL]